Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Assets (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Assets readings, the most recent being $88.5 million for Q4 2025.

  • On a quarterly basis, Assets rose 26.31% to $88.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $88.5 million, a 26.31% increase, with the full-year FY2025 number at $88.5 million, up 26.31% from a year prior.
  • Assets hit $88.5 million in Q4 2025 for Aligos Therapeutics, down from $109.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $263.1 million in Q3 2021 to a low of $70.1 million in Q4 2024.
  • Median Assets over the past 5 years was $140.7 million (2022), compared with a mean of $149.6 million.
  • Biggest five-year swings in Assets: plummeted 53.74% in 2024 and later increased 26.31% in 2025.
  • Aligos Therapeutics' Assets stood at $235.4 million in 2021, then crashed by 37.68% to $146.7 million in 2022, then grew by 3.3% to $151.5 million in 2023, then plummeted by 53.74% to $70.1 million in 2024, then increased by 26.31% to $88.5 million in 2025.
  • The last three reported values for Assets were $88.5 million (Q4 2025), $109.8 million (Q3 2025), and $134.7 million (Q2 2025) per Business Quant data.